Yuri E. Nikiforov, MD, PhD, discusses the reclassification of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, which has significantly influenced the thyroid cancer space.
Yuri E. Nikiforov, MD, PhD, professor of pathology and director of the Division of Molecular Anatomic Pathology at the University of Pittsburgh School of Medicine, discusses the reclassification of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), which has significantly influenced the thyroid cancer space.
Prior to 2016, the tumor, an encapsulated follicular variant of papillary thyroid cancer (EFVPTC), used to be called a type of cancer. Patients with EFVPTC were typically treated with thyroidectomy or radiation, conventional thyroid cancer treatments. However, researchers found these tumors to be low-risk and deemed lobectomy to be a usually sufficient treatment.
As a result, investigators conducted an international, multidisciplinary, retrospective study to further evaluate the tumor type. The panel of the study concluded that this type of tumor was indolent and ended up renaming the tumor, NIFTP.
Transcription
0:08 | The reclassification happened in 2016. It was preceded by about 2 years of work of the international groups that I had privileged to organize and lead. The reason for a classification was that we knew for many years that there is a group or a type of thyroid cancer that is extremely indolent. The patients do very well, and patients don't die of this disease. Yet, we were diagnosing it at an increasing rate. Patients were treated very aggressively. They were treated with the removal of the thyroid and given radioactive iodine. We felt that this is an overtreatment for these patients.
1:00 | So the international group of physicians got together and looked at all of the available information, and based on the data, it offered this data-driven reclassification of this cancer, and removed the word cancer, and called them as a non-cancerous or NIFTP. That in essence was needed in the field, and that was why this happened in 2016.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More